

Commentary

Open Access

## Is immunotherapy an effective treatment for Alzheimer's disease?

Federico Licastro\*<sup>1</sup> and Calogero Caruso<sup>2</sup>

Address: <sup>1</sup>Dipartimento di Patologia Sperimentale, Università di Bologna, Via S. Giacomo 14, 40126 Bologna, Italy and <sup>2</sup>Gruppo di Studio sull'Immunosenescenza, Dipartimento di Biopatologia e Metodologie Biomediche, Università di Palermo, Corso Tukory 211, 90134 Palermo, Italy

Email: Federico Licastro\* - [licastro@alma.unibo.it](mailto:licastro@alma.unibo.it); Calogero Caruso - [marcoc@unipa.it](mailto:marcoc@unipa.it)

\* Corresponding author

Published: 12 November 2004

Received: 19 October 2004

*Immunity & Ageing* 2004, **1**:3 doi:10.1186/1742-4933-1-3

Accepted: 12 November 2004

This article is available from: <http://www.immunityageing.com/content/1/1/3>

© 2004 Licastro and Caruso; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

Immunotherapy in patients with Alzheimer's disease (AD) is rapidly becoming a hot topic of modern geriatric and clinical gerontology. Current views see immunization with A $\beta$  peptide, the amyloidogenic protein found in senile plaque of AD patient's brains, or the infusion of preformed antibody specific for human A $\beta$ , as possible therapeutic approaches to improve the cognitive status in the disease. Animal models of the disease have provided positive results from both approaches. Thus, an initial clinical trial using immunization with human A $\beta$  in AD patients was started, but then shortly halted because of an unusually high incidence (6%) of meningoencephalitis. A long and currently ongoing debate in the scientific community about the pro or contra of vaccination or passive immunization with A $\beta$  in AD is thereafter started. Here, the authors would like to stress few points of concern regarding these approaches in clinical practice.

Immunotherapy in patients with Alzheimer's disease (AD) is rapidly becoming a hot topic of modern geriatric and clinical gerontology. M.E. Weksler [1] in the article entitled "The immunotherapy of Alzheimer's disease" published in *Immunity and Ageing* discussed this theme.

Current views see immunization with A $\beta$  peptide, the amyloidogenic protein found in senile plaque of AD patient's brains, or the infusion of preformed antibody specific for human A $\beta$ , as possible therapeutic approaches to improve the cognitive status in the disease.

Animal models of the disease have provided positive results from both approaches, since either vaccination with human A $\beta$  or infusion of preformed antibodies specific for A $\beta$ , have resulted in a decrease of amyloid plaques density in the brain of amyloid precursor protein (APP) transgenic mice [2,3]. Improved memory performances

after A $\beta$  vaccine on APP transgenic mice have also been claimed [4]. Several other studies from transgenic mice have there after reinforced the suggestion that vaccination or passive immunotherapy might result in a relevant clinical effect in human patients (see the Weksler article [1]).

An initial clinical trial using immunization with human A $\beta$  in AD patients was started and then shortly halted because of an unusually high incidence (6%) of meningoencephalitis (see the Weksler article [1]). A long and currently ongoing debate in the scientific community about the pro or contra of vaccination or passive immunization with A $\beta$  in AD is thereafter started.

Here, we would like to stress few points of concern regarding these approaches in clinical practice.

1) The claimed animal model for AD is unfortunately incomplete even if useful model for the human disease.

2) Vaccination with human A $\beta$  in mice induces an immune response against a foreign protein, i.e. human A $\beta$ , and the mouse A $\beta$  homolog does not appear to be involved. On the contrary, A $\beta$  vaccination in man may potentially induce an autoimmune like disease in the brain and other peripheral tissues of susceptible patients. At the moment we do not have the ability to predict which patients will suffer destructive immune responses.

3) The effects of both vaccination or passive immune therapy in AD brains might be non-specific, as already suggested by a recent report [5] and by the original histopathological investigation from AD patients deceased after meningoencephalitis [6]. This notion was then reinforced by the report of these authors [7].

4) Vaccine therapy is not always effective in the elderly, since immune defects of variable degree are often present in old persons [8]. In old clinically ill AD patients this immune activation might fail or activate noxious auto-aggressive immune responses. Once again we cannot predict which patient will experience one or the other condition after the vaccination.

5) Historically vaccination has been successful in the prevention of the diseases much and much less in the therapy of ongoing diseases. A significant gain would be achieved by A $\beta$  vaccination or passive immune therapy, if these manipulations will work in the very early stages of the disease. At the moment, no clinical data on this topic are available and those from animal models have not extensively addressed this topic.

6) A general consideration on AD is also mandatory. In fact, clinical signs of dementia show up after extensive synapse and neuron loss have already occurred in the brain. How can an immune response restore an already compromised nervous circuit or revive dead neurons? The very modest decrement of cognitive deterioration rate claimed in a proportion of AD patients receiving the vaccine is a marginal therapeutic goal. In fact, the disease has not been cured, and the modest clinical slow down in the AD progression takes big prices, i.e. patients and care givers will continue to suffer the catastrophic effects of the disease for a longer time.

We feel that A $\beta$  vaccination and in a less extent passive immune therapy are now exciting experimental protocols for animal research and experimental neurology investigations, probably premature for clinical applications.

## References

1. Weksler ME: **The immunotherapy of Alzheimer's disease.** *Immunity Ageing* 2004 in press.
2. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandeventer C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: **Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.** *Nature* 1999, **400**:173-177.
3. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock : **Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.** *T Nat Med* 2000, **6**:916-919.
4. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: **A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.** *Nature* 2000, **408**:982-985.
5. Akiyama H, McGeer PL: **Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease.** *Nat Med* 2004, **10**:117-118.
6. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: **Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.** *Nat Med* 2003, **9**:448-425.
7. Nicoll JAR, Wilkinson D, Holmes C, Stear P, Markham H, Weller R: **reply.** *Nat Med* 2004, **10**:118-119.
8. Vasto S, Caruso C: **IMMUNITY&AGEING: a new journal looking at ageing from an immunological point of view.** *Immunity Ageing* 2004, **1**:1.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

